Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide

Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Title: Anti–B-cell maturation antigen chimeric antigen receptor T cell function against 2 multiple myeloma is enhanced in the presence of lenalidomide 3 Authors: 4 Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C. 5 Jones, Wendy Curtis, Patrick Carlson, Timothy G. Johnstone, David Kugler, Ronald J. 6 Hause, Yue Jiang, Lindsey Wimberly, Christopher R. Clouser, Heidi K. Jessup, Blythe 7 Sather, Ruth A. Salmon, and Michael O. Ports 8 9 Affiliations: 10 Juno Therapeutics, A Celgene Company, Seattle, Washington. 11 12 Running title: 13 Lenalidomide enhances anti-BCMA CAR T function 14 Keywords: multiple myeloma; lenalidomide; CAR T; BCMA; Immunology 15 Financial support: This study was funded by Juno Therapeutics, A Celgene Company. 16 17 Corresponding author: Melissa Works 18 400 Dexter Ave N Suite 1200 19 Seattle, WA 98109 20 [email protected] 21 Phone: 206-566-5731 22 23 Disclosure of conflicts of interest: All authors are employed by and have equity interest 24 in Juno Therapeutics, Inc, A Celgene Company. 25 Abstract: 246/250 words 26 Manuscript: 4540/5000 27 Figures: 6/7 1 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 References: 32/50 2 Supplementary Document: Yes 3 4 Portions of this work were presented in poster form at the 59th annual meeting of the 5 American Society of Hematology; Atlanta, GA; December 9, 2017. 6 2 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Key points 2 Anti-BCMA CAR T cell function is enhanced by lenalidomide during acute or chronic 3 stimulation. 4 RNA- and ATAC-seq data support elements of T-effector and memory-cell molecular 5 signatures. 3 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Abstract 2 Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells have 3 shown promising clinical responses in patients with relapsed/refractory multiple 4 myeloma. Lenalidomide, an immunomodulatory drug, potentiates T cell functionality, 5 drives antimyeloma activity, and alters the suppressive microenvironment; these 6 properties may effectively combine with anti-BCMA CAR T cells to enhance function. 7 Using an anti-BCMA CAR T, we demonstrated that lenalidomide enhances CAR T cell 8 function in a concentration-dependent manner. Lenalidomide increased CAR T effector 9 cytokine production, particularly under low CAR stimulation or in the presence of 10 inhibitory ligand programmed cell death 1 ligand 1. Notably, lenalidomide also enhanced 11 CAR T cytokine production, cytolytic activity, and activation profile relative to untreated 12 CAR T cells in chronic stimulation assays. This unique potentiation of both short-term 13 CAR T activity and long-term functionality during chronic stimulation prompted 14 investigation of the molecular profile of lenalidomide-treated CAR T cells. Signatures 15 from RNA sequencing and assay for transposase-accessible chromatin using 16 sequencing indicated that pathways associated with T-helper 1 response, cytokine 17 production, T cell activation, cell-cycle control, and cytoskeletal remodeling were altered 18 with lenalidomide. Finally, study of lenalidomide and anti-BCMA CAR T cells in a 19 murine, disseminated, multiple myeloma model indicated that lenalidomide increased 20 CAR T cell counts in blood and significantly prolonged animal survival. In summary, 21 preclinical studies demonstrated that lenalidomide potentiated CAR T activity in vivo in 22 low-antigen or suppressive environments and delayed onset of functional exhaustion. 4 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 These results support further investigation of lenalidomide and anti-BCMA CAR T cells 2 in the clinic. 3 4 5 6 7 8 9 10 11 12 13 14 15 16 5 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Introduction 2 Despite improvements in the treatment of newly diagnosed multiple myeloma, it remains 3 uncured, and nearly all patients relapse and become resistant to available treatments 4 (1). Based on the encouraging activity of chimeric antigen receptor (CAR) T cells 5 targeting CD19 in non-Hodgkin lymphoma, CAR T cells targeting plasma cells 6 expressing B-cell maturation antigen (BCMA) have been developed for multiple 7 myeloma (2). Although BCMA CAR T cells have shown promise in the clinic, an 8 immunosuppressive myeloma tumor microenvironment, including programmed cell 9 death 1 ligand 1 (PD-L1) expression (3), and the potential for activation-induced 10 exhaustion may limit the durable responses of CAR T cells in some patients (4). 11 Lenalidomide is an immunomodulatory drug indicated for the treatment of multiple 12 myeloma (5); it has pleiotropic effects that directly impair primary tumor growth and 13 modulate the immunosuppressive tumor microenvironment to help facilitate a more 14 robust antitumor inflammatory response (6,7). Studies have shown that lenalidomide 15 can directly increase in vitro T cell function, even in heavily treated patients with 16 progressive disease, irrespective of immunomodulatory-drug refractory status (8). 17 Lenalidomide has also been shown to increase acute in vitro and in vivo CAR T cell 18 functionality in several model systems with varying CAR constructs and indications 19 (9,10). For example, lenalidomide in combination with CS1-directed CAR T cells with a 20 CD28z endodomain was associated with increased secretion of T-helper (Th) 1– 21 associated cytokines, decreased secretion of Th2–associated cytokines, and increased 22 survival in tumor-bearing mice (10). Additional studies are required to refine 23 lenalidomide’s mechanism of action and investigate its application in a chronic CAR T– 6 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 stimulation setting in conditions of varying antigen density or in the presence of 2 inhibitory ligands such as PD-L1. 3 CAR T cells have unique functional properties that can be altered by the characteristics 4 of the single-chain variable fragment, choice of transmembrane and endodomain, and 5 manufacturing process—all of which determine CAR T fitness during long-term 6 stimulation (11). In this study, we sought to characterize a novel anti-BCMA CAR 7 construct and determine short- and long-term effects of lenalidomide on CAR T function. 8 In addition, immunomodulatory drugs have been shown to directly induce CD28 tyrosine 9 phosphorylation (12), suggesting that these drugs impinge on costimulatory signaling 10 pathways; however, the role of a 41BBz endodomain during immunomodulatory drug 11 application is unclear. To understand the complex nature of lenalidomide’s mechanism 12 of action, we applied RNA sequencing (RNA-seq) and assay for transposase-accessible 13 chromatin using sequencing (ATAC-seq) technology to determine whether these 14 functional differences were associated with changes in the regulatory networks involved 15 in T cell function and activation. Finally, we examined concurrent and delayed 16 administration of lenalidomide with a subcurative dose of anti-BCMA CAR T injection to 17 further identify potential clinical applications and dosing strategies. 18 19 Materials and methods 20 In vitro cytolytic, cytokine, and flow cytometry CAR T assessment 21 T cells obtained from peripheral blood samples from consenting healthy adult donors 22 and a patient with multiple myeloma refractory to pomalidomide were transduced to 7 Downloaded from mct.aacrjournals.org on September 23, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2019; DOI: 10.1158/1535-7163.MCT-18-1146 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 express a construct containing an extracellular BCMA-binding single-chain variable 2 fragment and intracellular 41BBz endodomain (65%-76% CAR+, Supplementary Figure 3 1A, Supplementary Table 1, Supplementary

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    40 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us